Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PNT2258 |
| Synonyms | |
| Therapy Description |
PNT2258 is an oligonucleotide that binds to DNA upstream of BCL-2 and prevents its transcription, potentially resulting in increased tumor cell apoptosis (PMID: 24832107, PMID: 24297683). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PNT2258 | PNT- 2258|PNT 2258 | BCL2 inhibitor 29 | PNT2258 is an oligonucleotide that binds to DNA upstream of BCL-2 and prevents its transcription, potentially resulting in increased tumor cell apoptosis (PMID: 24832107, PMID: 24297683). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02226965 | Phase II | PNT2258 | Wolverine: PNT2258 for Treatment of Patients With r/r DLBCL | Completed | USA | 1 |